Stay connected and up-to-date on the latest news and reports. It’s never been easier to know what’s going on in digital health.
.png)
Pear Therapeutics announced last week that they are looking into “strategic alternatives” that could bolster its current precarious financial situation. Pear has been on the public markets since late 2021, however, its stock price has declined over the last two years.
Read more
FDIC's decision to close SVB has had an immediate impact on startup and tech companies, including those in digital health. With rising interest rates, investors have become increasingly conservative with their investments, focusing on a more targeted investment strategy.
Read more.png)
Mental health has been a pioneering area for digital therapeutics and a keen area of focus for digital health in recent years. As per the latest industry reports, the global market for digital biomarkers is growing, with its value estimated to reach $16,174 million by 2028.
Read more%20(1).png)
There was a wide range of topics discussed at our HealthXL meetings this February. To make sure you’re not missing out on the insightful discussions between community members and to keep you plugged into the conversation, here are Tess' five meeting takeaways from the past month.
Read more.png)
A key component to ensuring the adoption of digital health products is market access and reimbursement. In this week’s blog, we explore France's new fast-track reimbursement pathway for digital health and how it compares to Germany's DiGA pathway.
Read more
The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint, we discussed the pharma sales models for DTx-drug combination products. In this blog, we’ve pulled out the top takeaways from this series.
Read more
Over the past month, our HealthXL community members have discussed the opportunities for digital health in retail healthcare, using real-world data (RWD) to increase market access and revenue generation in DTx partnerships among other topics. Here's a snapshot of expert insights from these meetings.
Read more.png)
In part two, Jeremy Sohn, Managing Partner at P74 Ventures, continues to explore why the wave of innovation in pharma happened too quickly and the primary forces driving the need for change.
Read more%20(1).png)
HealthXL community members and industry leaders from pharma, digital health companies and decentralized trials providers have come together to create this new tool to help sponsors select the best digital measurement technologies for clinical trial use.
Read more.png)
In this blog, Jeremy Sohn, Managing Partner at P74 Ventures, explores the complexity of innovation in the pharmaceutical industry, why it sometimes experiences friction, and what factors have contributed to pharma embracing innovation.
Read more.png)
This week we look back at some of the biggest news stories from January. Read about Google and DeepMind's MedPaLM, reflections on the Consumer Electronics Show, and more.
Read more.png)
After a booming few years of growth in digital health, things returned to a normal cadence in 2022. Yet not all was quiet either: the femtech market continued to grow and Europe launched its first-ever digital health action plan. In this blog, we recap the most notable developments in 2022.
Read more.png)
We’re back with part two of our three-part blog series on Digital Health 3.0. This week, Robert Garber, Partner at 7wireVentures, explores challenges within healthcare, barriers to technology adoption, and how digital health might just be the fix we need.
Read more%20(1).png)
2022 has been a jam-packed year at HealthXL full of in-person events, advisory reports and new product features. Thanks to our amazing community members and advisory team, we expect 2023 to be even more informative and eventful. In this blog, we recap on our top six highlights for the year.
Read more.png)
To kick things off this January, we are bringing you a three part blog series focused on the next phase of digital health - Digital Health 3.0 - authored by leading industry experts who succinctly explore how we’ve landed at this crossroads and hypothesize on what’s next for digital health.
Read more.png)
Over the past month, our HealthXL community members discussed new distribution channels for DTx, seeking capital for DTx products and digital health pharma partnerships, among other topics. We’ve put together a snapshot of five expert insights from these meetings.
Read more
To make sense of how the current environment is shaping business models in digital health, we convened 80+ key decision-makers and experts at our Global Gathering in Chicago. We are delighted to share our event recap and highlights from the expert discussions.
Read more